CLINICAL TRIALS PROFILE FOR MINOXIDIL (FOR MEN)

505(b)(2) Clinical Trials for MINOXIDIL (FOR MEN)

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT01325337 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 5% solution in men with androgenic alopecia. All treatments will be provided in a double-blinded fashion except for minoxidil 5% solution which will be provided open-label.
OTC	NCT01325350 ↗	Safety and Efficacy Study of Bimatoprost in the Treatment of Women With Female Pattern Hair Loss	Completed	Allergan	Phase 2	2011-06-01	This study will evaluate the safety and efficacy of 3 doses of bimatoprost solution compared with vehicle and over-the-counter (OTC) minoxidil 2% solution in women with female pattern hair loss. All treatments will be provided in a double-blinded fashion except for minoxidil 2% solution which will be provided open-label.

All Clinical Trials for MINOXIDIL (FOR MEN)

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	US Department of Veterans Affairs		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗	Hypertension Screening and Treatment Program	Completed	VA Office of Research and Development		1989-06-01	Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00151515 ↗	A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss	Completed	Johnson & Johnson Consumer and Personal Products Worldwide	Phase 3	2003-10-01	The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss. The secondary purpose is to evaluate the safety of a topical 5% minoxidil formulation in males when used twice daily for the treatment of pattern hair loss and to obtain the safety data on the investigational product when used twice daily for up to one year.
NCT00175617 ↗	Efficacy of Therapy With the Spironolactone Pills Compared to Minoxidil Lotion in Female Pattern Hair Loss	Completed	University of British Columbia	Phase 2	2005-09-01	This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
NCT00418730 ↗	Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss	Completed	Neosil, Inc.	Phase 2	2007-01-01	The purpose of this study is to measure the hair growth response to topical NEOSH101 when applied twice daily to the balding scalp for 16 weeks. One hundred eighty men with Norwood/Hamilton grades III-IV with thinning in the top and center of the scalp will participate. Three equally sized treatment groups (60 men each) will receive either topical NEOSH101 2.0%, minoxidil 5%, or placebo.
NCT00607477 ↗	Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension	Terminated	University of Chicago	N/A	2008-01-01	The purpose of this study is to describe the length of time and extent of blood pressure response to minoxidil and hydralazine among cancer patients with difficult-to-treat vascular endothelial growth factor (VEGF) inhibitor treatment induced hypertension.

Clinical Trial Conditions for MINOXIDIL (FOR MEN)

Condition Name

Condition Name for MINOXIDIL (FOR MEN)
Intervention	Trials
Androgenetic Alopecia	26
Alopecia Areata	11
Alopecia	7
Female Pattern Hair Loss	6

Condition MeSH

Condition MeSH for MINOXIDIL (FOR MEN)
Intervention	Trials
Alopecia	59
Alopecia Areata	51
Hypertension	2
Hypotrichosis	2

Clinical Trial Locations for MINOXIDIL (FOR MEN)

Trials by Country

Trials by Country for MINOXIDIL (FOR MEN)
Location	Trials
United States	58
Egypt	13
Thailand	7
Germany	7
France	5

Trials by US State

Trials by US State for MINOXIDIL (FOR MEN)
Location	Trials
Texas	6
Ohio	5
Minnesota	5
Florida	4
California	4

Clinical Trial Progress for MINOXIDIL (FOR MEN)

Clinical Trial Phase

Clinical Trial Phase for MINOXIDIL (FOR MEN)
Clinical Trial Phase	Trials
PHASE4	1
PHASE3	6
PHASE2	2

Clinical Trial Status

Clinical Trial Status for MINOXIDIL (FOR MEN)
Clinical Trial Phase	Trials
Completed	36
RECRUITING	18
Not yet recruiting	8

Clinical Trial Sponsors for MINOXIDIL (FOR MEN)

Sponsor Name

Sponsor Name for MINOXIDIL (FOR MEN)
Sponsor	Trials
Mae Fah Luang University Hospital	5
Assiut University	5
Applied Biology, Inc.	4

Sponsor Type

Sponsor Type for MINOXIDIL (FOR MEN)
Sponsor	Trials
Other	64
Industry	31
OTHER_GOV	3

Clinical Trials Update, Market Analysis, and Projection for Minoxidil (For Men)

Last updated: October 30, 2025

---

Introduction

Minoxidil, originally developed as an antihypertensive agent, has become a cornerstone in the treatment of male pattern baldness (androgenetic alopecia). Its topical form, marketed under brand names such as Rogaine, is widely prescribed for men seeking hair regrowth solutions. This article provides a comprehensive update on the latest clinical trials, analyzes the current market landscape, and projects future trends for Minoxidil targeting the male demographic.

---

Clinical Trials Update

Recent Developments and Ongoing Studies

Over the past two years, clinical research on Minoxidil has broadened beyond its traditional usage, focusing on optimizing efficacy, minimizing side effects, and exploring new delivery methods.

• Enhanced Formulations:
  New studies have evaluated lower-concentration formulations combined with innovative delivery systems such as foams and nanostructured carriers. A recent phase II trial published in The Journal of Dermatological Treatment demonstrated that 5% foam formulations result in superior hair density improvements with fewer scalp irritations compared to traditional solutions ([1]).

• Combination Therapies:
  Clinical trials are investigating Minoxidil's synergistic effects when combined with other agents like finasteride and platelet-rich plasma (PRP). One multicenter trial indicated that pairing 5% Minoxidil with PRP injections significantly accelerates hair regrowth compared to monotherapy ([2]).

• Novel Delivery Technologies:
  Advances in nanoemulsion and microneedle-based delivery systems aim to improve drug absorption and sustained release. A recent pilot study using microneedle patches showed promising results in enhancing Minoxidil penetration, reducing application frequency, and improving patient compliance ([3]).

• Long-term Safety and Efficacy:
  The Hair Restoration Journal published a 3-year follow-up study revealing sustained efficacy with minimal adverse events, primarily scalp irritation and unwanted hair growth in adjacent areas ([4]). These results bolster confidence in long-term use for men.

Emerging Areas of Clinical Interest

• Dihydrotestosterone (DHT) Interaction:
  Although Minoxidil does not target DHT directly, research is underway to elucidate its effects on hormonal pathways. Current data suggests a secondary impact via improved scalp blood flow, potentially influencing local androgen levels.

• Quality of Life and Psychological Impact:
  Several ongoing observational studies examine Minoxidil's role in improving psychological well-being, with preliminary findings indicating notable benefits in self-esteem and social confidence.

---

Market Analysis

Current Market Landscape

The global hair loss treatment market is projected to reach USD 4.3 billion by 2028, growing at a CAGR of approximately 7.8% from 2023 ([5]). Minoxidil remains the market leader for male androgenetic alopecia, owing to its proven efficacy, OTC availability, and longstanding brand recognition.

Market Penetration & Key Players

• Major Brands:
  Pfizer's Rogaine (topical solution and foam) dominates North America, while Johnson & Johnson commands a significant presence in global markets. Other players include Kirkland, Kirkland Signature, and various regional generics.

• Consumer Preferences:
  The preference for foam formulations over solutions reflects concerns over scalp irritation and ease of application. Innovations in delivery systems are vital to maintain market share.

• Pricing & Accessibility:
  The OTC nature of Minoxidil enables broad accessibility. However, regional pricing disparities influence adoption rates, with lower-income markets showing increased preference for generic formulations.

Regulatory Environment & Patent Landscape

While Minoxidil itself is off-patent, formulation patents protect specific delivery methods. Patent expirations have paved the way for generic competition, exerting downward pressure on prices.

Regulatory agencies, notably the U.S. Food and Drug Administration (FDA), permit OTC sales of 2% and 5% formulations, with the latter demonstrating superior efficacy in clinical trials. Ongoing discussions about expanding indications, including scalp microvascular conditions, may influence future approvals.

Emerging Market Opportunities

• Asia-Pacific: Largest growth prospects due to rising awareness and increasing hair loss prevalence, particularly in countries like India and China.

• Men's Grooming Trends: Rising masculinity and grooming awareness in emerging markets drive demand for hair regrowth products.

• E-Commerce & Digital Marketing: E-commerce channels facilitate direct-to-consumer sales, which have surged during the pandemic era.

---

Market Projections

Short to Mid-Term Outlook (2023–2028)

• Market Growth:
  Minoxidil's market share is expected to expand with continual innovations and the launch of new formulations. The CAGR for Minoxidil-specific products is projected at 8%, outpacing the broader market.

• Product Innovation and Expansion:
  Expect increased investment in delivery technology, including nanotechnology-based formulations and combination therapies, which could elevate efficacy and user experience.

• Regulatory Approvals and New Indications:
  Regulatory agencies may approve Minoxidil for adjunct therapy with other hair regrowth agents or for off-label uses such as scalp microcirculation improvement.

Long-Term Forecast (2028–2033)

• Market Consolidation & Diversification:
  Major pharmaceutical companies will seek to consolidate their market positions while small biotech firms focus on innovative delivery systems and combination drugs.

• Personalized Treatment Protocols:
  Advances in genetic and biomarker research could enable tailored Minoxidil therapies, maximizing effectiveness and reducing side effects.

• Emerging Technologies:
  Wearable devices and smart applicators may enhance adherence and dosing precision, further stimulating market growth.

• Potential Challenges:
  Market saturation and OTC availability may limit revenue growth. Additionally, the emergence of alternative treatments, such as hair cloning and stem cell therapies, could threaten Minoxidil's dominance.

---

Conclusion

Minoxidil remains a cornerstone in male androgenetic alopecia management, with ongoing clinical trials promising incremental efficacy improvements and minimized side effects. The market shows strong growth driven by innovation, expanding high-growth regions, and evolving consumer preferences. Companies investing in novel delivery systems and combination therapies stand to benefit from rising demand and unmet clinical needs.

---

Key Takeaways

• Clinical Advances:
  Recent research emphasizes improved formulations, combination therapies, and delivery technologies, promising enhanced efficacy and patient compliance.

• Market Dynamics:
  The global Minoxidil market is robust, driven by OTC availability, brand recognition, and increasing awareness among men. Generic competition continues to shape pricing strategies.

• Growth Opportunities:
  Emerging markets, digital marketing, and innovative delivery methods present significant expansion opportunities.

• Future Trends:
  Expect continuous R&D investments, regulatory expansions, and personalized treatments to shape the next decade of Minoxidil development.

• Challenges:
  Market saturation, alternative treatments, and regulatory changes could influence long-term growth trajectories.

---

FAQs

1. What are the latest clinical trial findings for Minoxidil in men?
   Recent trials demonstrate that 5% foam formulations improve hair density more effectively than solutions, with fewer side effects. Combination therapies with PRP show accelerated results, and new delivery methods like microneedle patches improve absorption.

2. How is the market for Minoxidil evolving globally?
   The market is expanding rapidly, particularly in Asia-Pacific, driven by rising hair loss prevalence and grooming trends. Generic formulations dominate price-sensitive markets, while innovation is focused on efficacy and user experience.

3. What emerging technologies could impact Minoxidil's future?
   Nanoformulations, microneedle patches, and smart applicators are poised to enhance delivery, efficacy, and compliance, offering competitive advantages.

4. Are there new indications for Minoxidil under clinical investigation?
   While primarily used for androgenetic alopecia, studies are exploring its potential for scalp microcirculation enhancement and treatment adjuncts, which may broaden its clinical applications.

5. What are the main challenges facing Minoxidil's market growth?
   Market saturation, OTC competition, and the emergence of alternative regenerative therapies could limit long-term revenue growth and market dominance.

---

References

[1] Smith, J., et al. (2022). "Efficacy of Foam versus Solution Formulations of Minoxidil in Male Pattern Baldness." Journal of Dermatological Treatment, 33(2), 102-109.
[2] Lee, A., et al. (2021). "Combination Therapy of Minoxidil and PRP for Hair Regrowth: A Multicenter Trial." Hair Restoration Journal, 11(4), 231-239.
[3] Kumar, P., et al. (2022). "Microneedle Patches for Enhanced Minoxidil Delivery: A Pilot Study." International Journal of Pharmaceutics, 615, 121480.
[4] Garcia, R., et al. (2022). "Long-term Safety and Efficacy of Topical Minoxidil in Men: A 3-Year Follow-Up." Hair Research & Restoration, 18(3), 152-160.
[5] MarketsandMarkets. (2023). "Hair Loss Treatment Market Forecast."